Document is current
Any future updates will be listed below
-
Authors
Ahn, Green
Banik, Steven M.
Miller, Caitlyn L. https://orcid.org/0000-0001-5120-7149
Riley, Nicholas M. https://orcid.org/0000-0002-1536-2966
Cochran, Jennifer R. https://orcid.org/0000-0002-6532-9873
Bertozzi, Carolyn R. https://orcid.org/0000-0003-4482-2754
-
Funding
Funding for this research was provided by:
National Science Foundation Graduate Research Fellowship
National Institute of General Medical Sciences F32 Postdoctoral Fellowship
U.S. Department of Health & Human Services | National Institutes of Health (K00CA21245403)
St. Baldrick’s / Stand Up 2 Cancer Pediatric Dream Team Translational Cancer Research Grant
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM058867)
- License Information
-
More Information
Article History
Received: 12 August 2020
Accepted: 10 February 2021
First Online: 25 March 2021
Competing interests
: Stanford University has filed patent applications relating to lysosome-targeting chimeras, which are licensed to Lycia Therapeutics, listing G.A., S.M.B. and C.R.B. as co-inventors. G.A., S.M.B., C.L.M., J.R.C. and C.R.B. are co-inventors on a patent application relating to PIP-LYTACs filed by Stanford University (docket number STAN-1780PRV). C.R.B. is a co-founder and Scientific Advisory Board member of Lycia Therapeutics, Palleon Pharmaceuticals, Enable Bioscience, Redwood Biosciences (a subsidiary of Catalent) and InterVenn Biosciences and a member of the Board of Directors of Eli Lilly & Company. J.R.C. is a founder of xCella Biosciences and Combangio Inc. and co-founder and director of Trapeze Therapeutics.
